ERBB2 and breast carcinoma: Fortunately, in recent years, HER2+ breast cancer has been regarded as a curable illness with a highly hopeful therapeutic outcome due to the emergence of targeted therapies directed against HER2 receptors, such as monoclonal antibodies (Mabs) (e.g., trastuzumab, pertuzumab), antibody-drug conjugates (ADCs) (e.g., trastuzumab emtansine, trastuzumab deruxtecan), and tyrosine kinase inhibitors (TKIs) (e.g., lapatinib, neratinib, tucatinib, and erlotinib) [3,4,5,6,7].